ArticleMolecular and cellular pediatrics2026

Durable treatment response to Trastuzumab deruxtecan in two patients with recurrent grade III anaplastic ependymoma.

Dietmar Krex et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.